Insulins

Last updated: January 18, 2022

Insulins

DEGHAS podle otázek

DEGHAS podle otázek

Thyroid cancer
Thyroid nodules and thyroid cancer: Pathology review
Hypoglycemics: Insulin secretagogues
Fats and lipids
Familial hypercholesterolemia
Hypercholesterolemia: Clinical
Miscellaneous hypoglycemics
Dyslipidemias: Pathology review
Hypertriglyceridemia
Abetalipoproteinemia
Anatomy of the thyroid and parathyroid glands
Insulins
Hyperlipidemia
Adrenal cortical carcinoma
Adrenal masses: Pathology review
Cushing syndrome
Hyperaldosteronism
Conn syndrome
Congenital adrenal hyperplasia
Primary adrenal insufficiency
Adrenal insufficiency: Pathology review
Pheochromocytoma
Neuroblastoma
Opsoclonus myoclonus syndrome (NORD)
Waterhouse-Friderichsen syndrome
Diabetes mellitus
Diabetes mellitus: Pathology review
Diabetes mellitus: Clinical
Esophageal cancer
Gastric cancer
Esophageal disorders: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Colorectal cancer
Barrett esophagus
Gastritis
Diabetic retinopathy
Diabetic nephropathy
Leg ulcers: Clinical
Liver anatomy and physiology
Benign liver tumors
Hepatocellular carcinoma
Acid reducing medications
Cirrhosis
Microscopic colitis
Ulcerative colitis
Gallbladder carcinoma
Cholangiocarcinoma
Wilson disease
Pancreatic cancer
Metabolic acidosis
Metabolic and respiratory acidosis: Clinical
Pancreatic neuroendocrine neoplasms
Zollinger-Ellison syndrome
Gigantism
Acromegaly
Viral hepatitis
Viral hepatitis: Pathology review
Viral hepatitis: Clinical
Hepatitis A and Hepatitis E virus
Hepatitis B and Hepatitis D virus
Hepatitis medications
Hyperthyroidism
Hyperthyroidism: Pathology review
Hyperthyroidism: Clinical
Graves disease
Thyroid eye disease (NORD)
Toxic multinodular goiter
Thyroid storm
Alcohol-associated liver disease
Alcohol use disorder
Fetal alcohol syndrome
Wernicke-Korsakoff syndrome
Hypokalemia
Hypokalemia: Clinical
Laxatives and cathartics
Antidiarrheals
Pituitary adenoma
Prolactinoma
Hyperprolactinemia
Hyperpituitarism
Gout
Gout and pseudogout: Pathology review
Joint pain: Clinical
Lesch-Nyhan syndrome
Diarrhea: Clinical
Helicobacter pylori
Antigout medications
Metabolic alkalosis
Metabolic and respiratory alkalosis: Clinical
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Respiratory acidosis
Osteoporosis
Osteoporosis medications
Gestational diabetes
Cholestatic liver disease
Alagille syndrome (NORD)
Malabsorption syndromes: Pathology review
Gallstones
Gallbladder disorders: Clinical
Biliary colic
Primary sclerosing cholangitis
Cirrhosis: Clinical
Cushing syndrome and Cushing disease: Pathology review
Cushing syndrome: Clinical
Portal hypertension
Managing diabetes during the holidays: Information for patients and families
Hemochromatosis
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Vitamins and minerals
Fat-soluble vitamin deficiency and toxicity: Pathology review
Abdominal pain: Clinical
Anatomy clinical correlates: Anterior and posterior abdominal wall
Abdominal trauma: Clinical
Acute pancreatitis
Chronic pancreatitis
Pancreatitis: Clinical
Pancreatitis: Pathology review
Endocrine system anatomy and physiology
Polycystic ovary syndrome
Gastrointestinal hormones
Multiple endocrine neoplasia
Multiple endocrine neoplasia: Pathology review
MEN syndromes: Clinical
Autoimmune polyglandular syndrome type 1 (NORD)
Atherosclerosis and arteriosclerosis: Pathology review
Arterial disease
Bowel obstruction
Small bowel ischemia and infarction
Pancreas histology
Hyperthyroidism medications
Liver histology
Hypothyroidism
Hypothyroidism medications
Gastrointestinal bleeding: Clinical
Gastrointestinal bleeding: Pathology review
Pituitary gland histology
Mineralocorticoids and mineralocorticoid antagonists
Hypertension: Clinical
Non-alcoholic fatty liver disease
Hashimoto thyroiditis
Riedel thyroiditis
Euthyroid sick syndrome
Subacute granulomatous thyroiditis
Tuberculosis: Pathology review
Lactose intolerance
Celiac disease
Celiac disease: Nursing process (ADPIE)
Malabsorption: Clinical
Acid-base disturbances: Pathology review
Acid-base map and compensatory mechanisms
The role of the kidney in acid-base balance

Flashcards

Insulins

0 of 10 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 3 complete

USMLE® Step 2 style questions USMLE

0 of 4 complete

A 26-year-old man comes to his primary care physician for a routine visit. He has no acute complaints and is feeling well. Medical history is notable for type I diabetes mellitus. The patient takes insulin glargine at night and insulin aspart three times a day before meals. He has been adherent to his medications but reports getting pre-prandial fingerstick glucose measurements of 120-145 mg/dL. Temperature is 37.1°C (98.8°F), pulse is 70/min, and blood pressure is 107/73 mmHg. The physical exam is non-contributory. Laboratory testing is ordered, revealing a fasting blood glucose of 130 mg/dL and hemoglobin A1c of 8.0%. Which of the following is the most appropriate next step in the management of this patient?  

Transcript

Watch video only

Insulin is a type of peptide hormone that reduces the amount of glucose in the blood. It is produced in the pancreas by beta cells. These cells are found within clusters of endocrine cells called the Islets of Langerhans, which are distributed across the pancreas. If the body is unable to produce enough insulin, then insulin therapy is used to keep the blood glucose low.

Insulin’s main function is to facilitate the transport of glucose from the blood into the various insulin-responsive tissues like muscle cells and adipose tissue. This hormone binds to insulin receptors on the surface of the cell membrane. Now, these receptors have two alpha and two beta subunits. Alpha subunits are located outside of the cell and they bind insulin; while two beta subunits are located within the cell and they have tyrosine kinase activity which carries signals into the cell. Once stimulated, insulin receptors cause intracellular storage vesicles, which contain glucose transport proteins called GLUT4, to fuse with the cell membrane. Next, the GLUT4 proteins embed themselves into the membrane and allow glucose to move into the cell.

As a result, insulin promotes glucose uptake and glycogenesis, which is the conversion of glucose to glycogen. Glycogenesis is the process that takes place in the liver and skeletal muscles. When glycogen storage capacity is reached, insulin promotes glycolysis, which is the breakdown of glucose to pyruvate. It also stimulates lipogenesis, the synthesis of fatty acids and triglycerides in the liver and adipose tissue; and amino acid uptake and protein synthesis in skeletal muscles.

Finally, insulin activates Na+/K+- ATPase pumps and shifts potassium into intracellular space, thereby decreasing potassium levels in the blood. On the flip side, insulin inhibits glycogenolysis, which stands for the breakdown of glycogen; and gluconeogenesis, which is glucose production from lactic acids and noncarbohydrate molecules. Finally, insulin inhibits lipolysis, the breakdown of lipids; and proteolysis, the breakdown of proteins.

Type 1 diabetes mellitus, which most commonly affects children and adolescents, arises when a person’s own T cells attack the pancreas. Normally, maturing T cells in our body go through a process called “self-tolerance” where the T cells that would attack our own body are eliminated. In type 1 diabetes, there is a genetic abnormality which causes the loss of self-tolerance among T cells that target the beta cells. The result is the destruction of the beta cells which leads to decreased insulin production and hyperglycemia, or increased blood glucose.

Type 2 diabetes is caused by insulin resistance in the cells of the body. When blood glucose rises after a meal, the pancreas produces insulin as a response. Since the peripheral cells are resistant to insulin, they do not take in the glucose, so the pancreas has to produce even more insulin. Eventually, the poor pancreas gets so overworked that the beta cell starts to atrophy, which leads to decreased insulin production and high blood glucose levels.

In order to correct the insulin deficiency found in Type 1 diabetes and later stages of type 2 diabetes, exogenous insulins can be used. Insulin is administered subcutaneously because they can be broken down in the GI tract. Insulin is typically administered through syringes or insulin pens. When injected into the abdominal region, the absorption is the quickest, followed by arms, thighs, and buttocks. Some diabetics prefer the insulin pump since insulin dosages are programmed into the device and will be delivered subcutaneously throughout the day, thus preventing the need for multiple daily insulin injections.

Now, there are multiple categories of insulin therapies, more commonly referred to as insulin preparations. These preparations are categorized according to their onset of action and duration of effect; and they include rapid-acting, short-acting, intermediate-acting, long-acting, and ultra long-acting insulins.

Rapid-acting and short-acting insulins are used for bolus insulin regimen, where they are taken before each meal to counteract the post-meal increase in blood glucose. Intermediate-acting, long-acting, and ultra long-lasting insulins are used for basal insulin regimen to maintain a steady background level of insulin throughout the day. They are given once or twice daily to regulate the basal, or fasting blood glucose, level.

Next, there's a basal-bolus regimen where a basal insulin is used to maintain fasting blood glucose levels, and a bolus insulin is taken before meals. Lastly, is the sliding-scale regimen. This regimen is typically reserved for hospital settings where a person’s blood glucose level could fluctuate rapidly due to metabolic stressors like infections or other illnesses. In this regimen, every 4-6 hours, the person’s glucose level is measured and an appropriate dosage of short acting insulin is given. Finally, it’s important to note that insulins are the preferred medications in managing diabetes in pregnancy and breastfeeding.

Now let’s look at each class of insulin, starting with rapid-acting insulins, which include insulin aspart, lispro, and glulisine. These medications are given subcutaneously and they are actually modified versions of regular insulin with different sequences of amino acids. This makes them less stable, and they break down into single monomers soon after injection. Rapid-acting insulins begin working within 5 to 15 minutes of administration, with a peak effect at 1 hour. Their effects last for 3 to 4 hours. These insulins are injected right before a meal or they can be used in insulin pumps. They are also the preferred insulin for treating diabetic ketoacidosis.

Next are the short-acting insulins, or regular insulin, which is the only type of insulin that could be given subcutaneously and intravenously. Regular insulin in the body is generally produced and stored as a hexamer, which is simply a term used to describe a single unit of 6 insulin molecules. This structure allows insulin to remain stable within the body, and break down into individual monomers in order to become active. Thus, regular insulin only begins working 30 minutes after administration and its effect peaks at 2-3 hours. Its duration of action lasts between 5-8 hours and, besides diabetes melitus, it can be used to treat hyperkalemia.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Insulin lispro: a fast-acting insulin analog" Am Fam Physician (1998)
  5. "Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation" Pharmaceutical Research (2017)
  6. "Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus" Cochrane Database of Systematic Reviews (2016)